宣肺通络平喘汤对慢性阻塞性肺疾病急性加重期患者免疫功能、炎症反应调控的机制研究  

Study on the Regulatory Mechanism of Xuanfei Tongluo Pingchuan Decoction on Immune Function and Inflammatory Response in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

作　　者：李仙珍 朱国清[1] 唐丽丽 陈贺 LI Xian-Zhen;ZHU Guo-Qing;TANG Li-Li;CHEN He(Tangshan Hospital of Traditional Chinese Medicine,Tangshan 063000 Hebei,China;Tangshan Workers’Hospital,Tangshan 063000 Hebei,China)

机构地区：[1]唐山市中医医院,河北唐山063000 [2]唐山市工人医院,河北唐山063000

出　　处：《广州中医药大学学报》2024年第1期33-41,共9页Journal of Guangzhou University of Traditional Chinese Medicine

基　　金：国家重点研究计划项目(编号:2018YFC1704803);河北省中医药管理局中药类科研计划项目(编号:2022543)。

摘　　要：【目的】分析宣肺通络平喘汤治疗慢性阻塞性肺疾病急性加重期(AECOPD)患者的临床疗效及其对免疫功能、炎症反应的调控机制。【方法】采用回顾性研究方法,收集122例痰瘀阻肺型AECOPD患者,根据治疗方案的不同将患者分为观察组和对照组,每组各61例。对照组给予常规西药治疗,观察组在对照组的基础上联合宣肺通络平喘汤治疗,疗程为14 d。观察2组患者治疗前后肺功能指标、6 min步行距离(6MWD)、慢性阻塞性肺疾病评估测试(CAT)评分、免疫功能指标、血清炎症因子指标的变化情况,比较2组患者的临床疗效和不良反应总发生率。【结果】(1)疗效方面,治疗14 d后,观察组的总有效率为95.08%(58/61),对照组为77.05%(47/61),组间比较,观察组的疗效明显优于对照组(P<0.01)。(2)肺功能方面,治疗后,2组患者的第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、最大呼气流量(PEF)等肺功能指标均较治疗前明显改善(P<0.05),且观察组对各项肺功能指标的改善作用均明显优于对照组(P<0.01)。(3)6MWD和CAT评分方面,治疗后,2组患者的6MWD均较治疗前明显提高(P<0.05),CAT评分均较治疗前明显降低(P<0.05),且观察组对6MWD的提高作用及对CAT评分的降低作用均明显优于对照组(P<0.01)。(4)免疫功能方面,治疗后,2组患者的T淋巴细胞亚群CD4^(+)、CD4^(+)/CD8^(+)水平均较治疗前明显升高(P<0.05),CD8^(+)水平均较治疗前明显降低(P<0.05),且观察组对T淋巴细胞亚群CD4^(+)、CD4^(+)/CD8^(+)水平的升高作用及对CD8^(+)水平的降低作用均明显优于对照组(P<0.01)。(5)血清炎症因子方面,治疗后,2组患者的血清C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)水平均较治疗前明显降低(P<0.05),且观察组对血清CRP、TNF-α水平的降低作用均明显优于对照组(P<0.01)。(6)不良反应方面,观察组的不良反应总发生率为3.28%(2/61),对照组为6.56%(4/61),组间比较,差异无统计�Objective To investigate the clinical efficacy of Xuanfei Tongluo Pingchuan Decoction in treating patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)and to explore its regulatory mechanism on immune function and inflammatory response.Methods A retrospective study was conducted in 122 patients with AECOPD of phlegm-stasis obstructing lung type,and the patients were divided into an observation group and a control group according to the therapy,with 61 patients in each group.The control group was treated with conventional western medicine,and the observation group was treated with Xuanfei Tongluo Pingchuan Decoction on the basis of treatment for the control group.The treatment lasted for 14 days.Before and after treatment,the patients of the two groups were observed in the changes of pulmonary function indicators,6-minute walking distance(6MWD),COPD Assessment Test(CAT)scores,immune function indicators,and serum inflammatory factors.After treatment,the clinical efficacy and the overall occurrence rate of the adverse reactions were compared between the two groups.Results(1)After 14 days of treatment,the total effective rate of the observation group was 95.08%(58/61),and that of the control group was 77.05%(47/61).The intergroup comparison showed that the therapeutic effect of the observation group was significantly superior to that of the control group(P<0.01).(2)After treatment,pulmonary function indexes such as the forced expiratory volume in one second(FEV1),forced vital capacity(FVC),and peak expiratory flow(PEF)of the two groups were significantly improved compared with those before treatment(P<0.05),and the effect on improving all pulmonary function indexes in the observation group was significantly superior to that in the control group(P<0.01).(3)After treatment,the 6MWD of the two groups were significantly higher(P<0.05)and the CAT scores were significantly lower than those before treatment(P<0.05),and the observation group was significantly superior to the control group in terms

关 键 词：宣肺通络平喘汤 慢性阻塞性肺疾病急性加重期 痰瘀阻肺 肺功能 免疫功能 炎症反应 

分 类 号：R259.63[医药卫生—中西医结合]